JP2013513588A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013513588A5 JP2013513588A5 JP2012542580A JP2012542580A JP2013513588A5 JP 2013513588 A5 JP2013513588 A5 JP 2013513588A5 JP 2012542580 A JP2012542580 A JP 2012542580A JP 2012542580 A JP2012542580 A JP 2012542580A JP 2013513588 A5 JP2013513588 A5 JP 2013513588A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- group
- parkinson
- compound
- stroke
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 20
- 201000010099 disease Diseases 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 16
- 208000018737 Parkinson disease Diseases 0.000 claims 13
- 208000006011 Stroke Diseases 0.000 claims 11
- 208000024827 Alzheimer disease Diseases 0.000 claims 10
- 206010011878 Deafness Diseases 0.000 claims 10
- 206010012289 Dementia Diseases 0.000 claims 10
- 208000023105 Huntington disease Diseases 0.000 claims 10
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 10
- 208000026072 Motor neurone disease Diseases 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 208000028389 Nerve injury Diseases 0.000 claims 10
- 208000008589 Obesity Diseases 0.000 claims 10
- 208000002193 Pain Diseases 0.000 claims 10
- 208000006289 Rett Syndrome Diseases 0.000 claims 10
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 10
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 10
- 230000006931 brain damage Effects 0.000 claims 10
- 231100000874 brain damage Toxicity 0.000 claims 10
- 208000029028 brain injury Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 206010015037 epilepsy Diseases 0.000 claims 10
- 230000010370 hearing loss Effects 0.000 claims 10
- 231100000888 hearing loss Toxicity 0.000 claims 10
- 208000016354 hearing loss disease Diseases 0.000 claims 10
- 208000028867 ischemia Diseases 0.000 claims 10
- 208000005264 motor neuron disease Diseases 0.000 claims 10
- 201000006417 multiple sclerosis Diseases 0.000 claims 10
- 210000005036 nerve Anatomy 0.000 claims 10
- 230000008764 nerve damage Effects 0.000 claims 10
- 235000020824 obesity Nutrition 0.000 claims 10
- 210000000578 peripheral nerve Anatomy 0.000 claims 10
- 208000033808 peripheral neuropathy Diseases 0.000 claims 10
- 208000020431 spinal cord injury Diseases 0.000 claims 10
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 9
- 206010021143 Hypoxia Diseases 0.000 claims 9
- 230000007954 hypoxia Effects 0.000 claims 9
- 238000002054 transplantation Methods 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims 2
- 108091008551 RET receptors Proteins 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000005275 alkylenearyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000005155 neural progenitor cell Anatomy 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 125000002015 acyclic group Chemical group 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000005237 alkyleneamino group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 229940125507 complex inhibitor Drugs 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 0 CCN(CC)*c(cc1N(CC2)CCN2C(c2c(C(F)(F)F)ccc(F)c2)=O)ccc1OC Chemical compound CCN(CC)*c(cc1N(CC2)CCN2C(c2c(C(F)(F)F)ccc(F)c2)=O)ccc1OC 0.000 description 1
- CMLVHSVFSYNMGM-WYMLVPIESA-N CCN(CC)CCCC(C)Nc1cc(/C=C/c2ccccc2Cl)nc2c1ccc(Cl)c2 Chemical compound CCN(CC)CCCC(C)Nc1cc(/C=C/c2ccccc2Cl)nc2c1ccc(Cl)c2 CMLVHSVFSYNMGM-WYMLVPIESA-N 0.000 description 1
- ZEOYUYLFSSQGPV-UHFFFAOYSA-N CCOC(CNC(N(CC(Nc([n](-c1ccc(C)cc1)nc1C)c1-c1ccccc1)=O)C(C)C)=O)=O Chemical compound CCOC(CNC(N(CC(Nc([n](-c1ccc(C)cc1)nc1C)c1-c1ccccc1)=O)C(C)C)=O)=O ZEOYUYLFSSQGPV-UHFFFAOYSA-N 0.000 description 1
- QRZKCAGDVVWBDJ-UHFFFAOYSA-N COc1cccc(Cc2n[s]c(N(CCC3)C3C(O)=O)n2)c1 Chemical compound COc1cccc(Cc2n[s]c(N(CCC3)C3C(O)=O)n2)c1 QRZKCAGDVVWBDJ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28585809P | 2009-12-11 | 2009-12-11 | |
| US61/285,858 | 2009-12-11 | ||
| PCT/EP2010/069535 WO2011070177A2 (en) | 2009-12-11 | 2010-12-13 | Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013513588A JP2013513588A (ja) | 2013-04-22 |
| JP2013513588A5 true JP2013513588A5 (enExample) | 2014-02-06 |
Family
ID=43502911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012542580A Pending JP2013513588A (ja) | 2009-12-11 | 2010-12-13 | Ｇｄｎｆファミリーリガンド（ｇｆｌ）のミメティックまたはｒｅｔシグナル経路活性化因子を用いた、神経系細胞の生存を容易にするための方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8901129B2 (enExample) |
| EP (1) | EP2509953B1 (enExample) |
| JP (1) | JP2013513588A (enExample) |
| CN (2) | CN103180297A (enExample) |
| AU (1) | AU2010329847A1 (enExample) |
| BR (1) | BR112012014022A2 (enExample) |
| CA (1) | CA2783934A1 (enExample) |
| MX (1) | MX2012006580A (enExample) |
| WO (1) | WO2011070177A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160136159A1 (en) * | 2012-09-17 | 2016-05-19 | Chemedest Ltd. | Method for Treating Peripheral Neuropathy |
| CN103146798B (zh) * | 2013-02-25 | 2015-04-08 | 潍坊易思特生物科技有限公司 | 一种测定重组人胶质细胞源性神经营养因子活性的细胞学方法 |
| CN105640955B (zh) * | 2016-01-28 | 2019-12-24 | 昆明医科大学 | 一种Aminoquinol的新用途 |
| CN105906608B (zh) * | 2016-05-03 | 2018-10-19 | 中山大学 | 8-氨基喹啉-松果体素杂联体及其药物组合物 |
| AU2017263174A1 (en) * | 2016-05-13 | 2018-12-13 | Instituto de Medicina Molecular João Lobo Antunes | Methods of treating diseases associated with ILC3 cells |
| RU2019120431A (ru) * | 2016-12-21 | 2021-01-22 | Альцекьюэ Фарма Аб | Производные триазинтриона и их использование в качестве модуляторов нейротрофиновых рецепторов и рецепторов тирозинкиназ |
| CN107337641B (zh) * | 2017-07-01 | 2020-04-28 | 广东医科大学 | 一种4-柔性胺基-2-芳乙烯基喹啉类衍生物及其制备方法和应用 |
| MX2023011655A (es) | 2021-03-31 | 2023-10-11 | Cambridge Entpr Ltd | Inhibidores terapeuticos de la se?alizacion de gdf15. |
| IL309027A (en) | 2021-06-03 | 2024-02-01 | Fundac?O D Anna De Sommer Champalimaud E Dr Carlos Montez Champalimaud | Neuro-messenger units that control ILC2 and obesity in brain fat cell circuit findings |
| EP4413119A1 (en) | 2021-11-12 | 2024-08-14 | Axent Biosciences Inc. | Methods for production of functional neurons |
| CN119894875A (zh) * | 2022-07-28 | 2025-04-25 | 基因密码公司 | 作为用于治疗神经障碍的神经保护剂的具有GFRα1-RET活性的[4-[5-(甲基磺酰基)-苯基]哌嗪-1-基]-(苯基)甲酮衍生物及类似化合物 |
| KR20250044337A (ko) | 2022-07-28 | 2025-03-31 | 제네코드 | 신규의 설폰아마이드 및 신경보호제 및/또는 신경회복제로서의 이의 용도 |
| CN120035580A (zh) | 2022-10-14 | 2025-05-23 | 基因密码公司 | 新型哌嗪基磺胺类药物及其作为神经保护剂和/或神经修复剂的用途 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2531011A (en) * | 1949-01-22 | 1950-11-21 | Sterling Drug Inc | 3-chloro-9-[2-(2-hydroxyethylamino)-ethylamino] acridine and method for its production |
| US3232945A (en) * | 1962-08-13 | 1966-02-01 | S E Massengill Company | 7,8,9,10-tetrahalo-6h-cyclohepta-(b)-quinolines |
| US3458525A (en) * | 1966-07-01 | 1969-07-29 | American Home Prod | Spiro(indoline-3,2'-thiazolidine)-2-one and derivatives |
| US4534899A (en) | 1981-07-20 | 1985-08-13 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
| US4426330A (en) | 1981-07-20 | 1984-01-17 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| DK569087A (da) | 1986-10-31 | 1988-05-01 | Sumitomo Pharma | Quinolin-derivater, deres fremstilling og anvendelse |
| WO1988007852A1 (en) | 1987-04-06 | 1988-10-20 | Innovative Therapeutics Corporation | Liposome entrapped magnesium |
| WO1988007851A1 (en) | 1987-04-06 | 1988-10-20 | Innovative Therapeutics Corporation | Liposome entrapped n-methyl-d-aspartate receptor blockers |
| US5284876A (en) | 1988-02-26 | 1994-02-08 | Neuromedica, Inc. | Method of treating tardive dyskinesia using dopaminergic agents of prodrugs of therapeutic agents |
| US4939174A (en) | 1988-02-26 | 1990-07-03 | Shashoua Victor E | Appetite suppression with dopamine-fatty acid conjugates |
| US4933324A (en) | 1988-02-26 | 1990-06-12 | Shashoua Victor E | Fatty acid-neuroactive drug conjugate as a prodrug |
| US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5019400A (en) | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
| US5227170A (en) | 1989-06-22 | 1993-07-13 | Vestar, Inc. | Encapsulation process |
| US4999430A (en) * | 1989-07-31 | 1991-03-12 | Warner-Lambert Company | Derivatives of 1,2,3,4-tetrahydro-9-acrisinamine |
| US5154924A (en) | 1989-09-07 | 1992-10-13 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
| US5672683A (en) | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
| US5182107A (en) | 1989-09-07 | 1993-01-26 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
| CA2025907A1 (en) | 1989-09-21 | 1991-03-22 | Franklin D. Collins | Method of transporting compositions across the blood brain barrier |
| US5356633A (en) | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
| US5527528A (en) | 1989-10-20 | 1996-06-18 | Sequus Pharmaceuticals, Inc. | Solid-tumor treatment method |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| CA2029497C (en) * | 1989-11-08 | 2002-06-04 | Kunihiro Ninomiya (Deceased) | 4-acylaminopyridine derivative |
| JPH03236315A (ja) | 1989-12-05 | 1991-10-22 | Nippon Oil & Fats Co Ltd | 抗精神病薬 |
| US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
| US5469854A (en) | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5109921A (en) | 1991-04-29 | 1992-05-05 | Halliburton Company | Controlled weak point for wireline cable |
| JP3220180B2 (ja) | 1991-05-23 | 2001-10-22 | 三菱化学株式会社 | 薬剤含有タンパク質結合リポソーム |
| US5521291A (en) | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
| NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
| US5260308A (en) | 1991-11-06 | 1993-11-09 | Mayo Foundation For Medical Education And Research | Method to increase permeability of the blood-nerve/brain barriers to proteins |
| EP0614375A1 (en) | 1991-11-26 | 1994-09-14 | Alkermes, Inc. | Process for the preparation of transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
| WO1993017668A1 (en) | 1992-03-12 | 1993-09-16 | Alkermes Controlled Therapeutics, Inc. | Controlled release acth containing microspheres |
| WO1994002178A1 (en) | 1992-07-27 | 1994-02-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Targeting of liposomes to the blood-brain barrier |
| US5583020A (en) | 1992-11-24 | 1996-12-10 | Ribozyme Pharmaceuticals, Inc. | Permeability enhancers for negatively charged polynucleotides |
| JP3351476B2 (ja) | 1993-01-22 | 2002-11-25 | 三菱化学株式会社 | リン脂質誘導体及びそれを含有するリポソーム |
| US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
| US5462854A (en) | 1993-04-19 | 1995-10-31 | Beckman Instruments, Inc. | Inverse linkage oligonucleotides for chemical and enzymatic processes |
| US5534259A (en) | 1993-07-08 | 1996-07-09 | Liposome Technology, Inc. | Polymer compound and coated particle composition |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5417978A (en) | 1993-07-29 | 1995-05-23 | Board Of Regents, The University Of Texas System | Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5591721A (en) | 1994-10-25 | 1997-01-07 | Hybridon, Inc. | Method of down-regulating gene expression |
| US5512295A (en) | 1994-11-10 | 1996-04-30 | The Board Of Trustees Of The Leland Stanford Junior University | Synthetic liposomes for enhanced uptake and delivery |
| CA2294988C (en) | 1997-07-01 | 2015-11-24 | Isis Pharmaceuticals Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| US6235769B1 (en) | 1997-07-03 | 2001-05-22 | Sugen, Inc. | Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase |
| WO2000050050A1 (en) | 1999-02-23 | 2000-08-31 | Isis Pharmaceuticals, Inc. | Multiparticulate formulation |
| US6287860B1 (en) | 2000-01-20 | 2001-09-11 | Isis Pharmaceuticals, Inc. | Antisense inhibition of MEKK2 expression |
| FI20000480A0 (fi) | 2000-03-01 | 2000-03-01 | Orion Yhtymae Oyj | Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina |
| US7001905B2 (en) * | 2000-03-15 | 2006-02-21 | Warner-Lambert Company | Substituted diarylamines as MEK inhibitors |
| JP2006514917A (ja) * | 2002-07-09 | 2006-05-18 | アルファ リサーチ グループ， エルエルシー | パーキンソン病および遅発性ジスキネジーの処置のための組成物および方法 |
| US20040034019A1 (en) * | 2002-08-08 | 2004-02-19 | Ronald Tomlinson | Piperazine and piperidine derivatives |
| EP1551809A1 (en) * | 2002-10-09 | 2005-07-13 | Pfizer Products Inc. | Pyrazole compounds for treatment of neurodegenerative disorders |
| WO2005030128A2 (en) * | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Pyrazole modulators of metabotropic glutamate receptors |
| WO2005112913A1 (en) | 2004-05-20 | 2005-12-01 | The Scripps Research Institute | Transthyretin stabilization |
| CA2599992A1 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Acridine and quinoline dervatives as sirtuin modulators |
| GB0505086D0 (en) * | 2005-03-11 | 2005-04-20 | Glaxo Group Ltd | Compounds |
| EP1904491A2 (en) * | 2005-05-31 | 2008-04-02 | Vertex Pharmaceuticals Incorporated | Heterocycles useful as modulators of ion channels |
| DE202005008426U1 (de) | 2005-05-31 | 2005-09-15 | Ricon Sieb Und Foerdertechnik | Fördervorrichtung mit Fördertuch |
| EP1893192A4 (en) | 2005-06-08 | 2010-03-31 | Univ North Carolina | METHOD FOR ENABLING SURVIVAL OF NERVE CELLS BASED ON NON-PEPTIDIC AND PEPTIDIC BDNF NEUROTROPHINE MIMETICS |
| WO2008010984A2 (en) * | 2006-07-17 | 2008-01-24 | The Trustees Of The University Of Pennsylvania | Acridine activation of p53 and uses thereof |
| US7605265B2 (en) * | 2007-01-22 | 2009-10-20 | Biotechnology Research Corporation Ltd. | Heterodimers and methods of using them |
| US20080234267A1 (en) | 2007-03-20 | 2008-09-25 | Karen Elizabeth Lackey | Compounds and Methods of Treatment |
| EP2178842A2 (en) | 2007-08-22 | 2010-04-28 | Abbott GmbH & Co. KG | 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use |
| US7863295B2 (en) * | 2008-02-12 | 2011-01-04 | Children's Medical Center Corporation | Treatments for neuropathy |
| US20110045100A1 (en) | 2008-03-05 | 2011-02-24 | Georgetown University | Antimalarial Quinolines and Methods of Use Thereof |
| US10867398B2 (en) | 2017-11-21 | 2020-12-15 | Reliance Core Consulting LLC | Methods, systems, apparatuses and devices for facilitating motion analysis in an environment |
-
2010
- 2010-12-13 US US13/514,906 patent/US8901129B2/en active Active
- 2010-12-13 EP EP10790954.1A patent/EP2509953B1/en not_active Not-in-force
- 2010-12-13 CA CA2783934A patent/CA2783934A1/en not_active Abandoned
- 2010-12-13 WO PCT/EP2010/069535 patent/WO2011070177A2/en not_active Ceased
- 2010-12-13 BR BR112012014022A patent/BR112012014022A2/pt not_active IP Right Cessation
- 2010-12-13 CN CN2010800637467A patent/CN103180297A/zh active Pending
- 2010-12-13 MX MX2012006580A patent/MX2012006580A/es not_active Application Discontinuation
- 2010-12-13 JP JP2012542580A patent/JP2013513588A/ja active Pending
- 2010-12-13 AU AU2010329847A patent/AU2010329847A1/en not_active Abandoned
- 2010-12-13 CN CN201410513670.3A patent/CN104529945A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013513588A5 (enExample) | ||
| JP5277168B2 (ja) | 血小板過剰を治療するｂｃｌインヒビター | |
| JP2013545730A5 (enExample) | ||
| JP2012530779A5 (enExample) | ||
| JP2009504763A5 (enExample) | ||
| JP2010514832A5 (enExample) | ||
| SI3018132T1 (en) | Condensed imidazole derivatives useful as IDO inhibitors | |
| RU2013155586A (ru) | [1,3]оксазины | |
| JP2013006854A5 (enExample) | ||
| JP2015537020A5 (enExample) | ||
| EP3404029A3 (en) | Pyrimido-pyridazinone compounds and methods and use thereof | |
| RU2010119458A (ru) | 1,3,5-тризамещенное производное триазола | |
| EA201500050A1 (ru) | Бифтордиоксалан-амино-бензимидазольные ингибиторы киназы для лечения рака, аутоиммунного воспаления и нарушений цнс | |
| CY1109370T1 (el) | Παραγωγα οξαδιαζολονης ως ppar δελτα αγωνιστες | |
| JP2015508092A5 (enExample) | ||
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| JP2012523395A5 (enExample) | ||
| RU2016124136A (ru) | Дикетоны и гидроксикетоны в качестве активатора сигнального пути катенина | |
| RU2016131875A (ru) | Производные n-фениллактама, способные стимулировать нейрогенез, и их применение при лечении заболеваний нервной системы | |
| RU2013113634A (ru) | Агонисты рецепторов нейротрофинов и их применение в качестве лекарственных средств | |
| JP2007507494A5 (enExample) | ||
| RU2013130878A (ru) | Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx | |
| PH12012501863A1 (en) | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators | |
| JP2019535825A5 (enExample) | ||
| JP2017509676A5 (enExample) |